Molecular Templates, Inc. (MTEM)
After hours:
| Previous Close | 0.3353 |
| Open | 0.3396 |
| Bid | 0.3913 x 100 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.3326 - 0.4399 |
| 52 Week Range | 0.3000 - 5.3700 |
| Volume | |
| Avg. Volume | 10,110,760 |
| Market Cap | 2.644M |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.0500 |
| Earnings Date | Nov 25, 2024 - Nov 28, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireMolecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update
Monotherapy activity of long duration in patients who have progressed on checkpoint therapy via a novel immuno-oncology mechanism of action with PD-L1 ETB (MT-6402) programEarly indication of monotherapy activity in CTLA-4 ETB (MT-8421) program through T-reg depletion; no drug-related adverse events > grade 2Novel mechanism of action targeting CD38+ immune cells of B-cell, T-cell, and monocytic lineage representing enhanced potency in I&I without the need for conditioning therapy AUSTIN, Texas,
- GlobeNewswire
Molecular Templates, Inc. Provides Interim Update
Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients.Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in severe immune-mediated diseases. AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of a
